JP2024527028A5 - - Google Patents

Info

Publication number
JP2024527028A5
JP2024527028A5 JP2024504831A JP2024504831A JP2024527028A5 JP 2024527028 A5 JP2024527028 A5 JP 2024527028A5 JP 2024504831 A JP2024504831 A JP 2024504831A JP 2024504831 A JP2024504831 A JP 2024504831A JP 2024527028 A5 JP2024527028 A5 JP 2024527028A5
Authority
JP
Japan
Prior art keywords
cdr
sequence ids
light
sequence
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024504831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527028A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/074106 external-priority patent/WO2023009979A1/en
Publication of JP2024527028A publication Critical patent/JP2024527028A/ja
Publication of JP2024527028A5 publication Critical patent/JP2024527028A5/ja
Pending legal-status Critical Current

Links

JP2024504831A 2021-07-26 2022-07-25 抗ｌｉｇｈｔ抗体を用いて潰瘍性大腸炎を治療する方法 Pending JP2024527028A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163225675P 2021-07-26 2021-07-26
US63/225,675 2021-07-26
PCT/US2022/074106 WO2023009979A1 (en) 2021-07-26 2022-07-25 Methods of treating ulcerative colitis with anti-light antibodies

Publications (2)

Publication Number Publication Date
JP2024527028A JP2024527028A (ja) 2024-07-19
JP2024527028A5 true JP2024527028A5 (enExample) 2025-08-01

Family

ID=85087298

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024504831A Pending JP2024527028A (ja) 2021-07-26 2022-07-25 抗ｌｉｇｈｔ抗体を用いて潰瘍性大腸炎を治療する方法

Country Status (5)

Country Link
US (1) US20240158522A1 (enExample)
EP (1) EP4376888A4 (enExample)
JP (1) JP2024527028A (enExample)
CN (1) CN117940163A (enExample)
WO (1) WO2023009979A1 (enExample)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA021255B1 (ru) * 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Антагонистические моноклональные антитела человека, специфичные в отношении light человека
WO2010111180A1 (en) * 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
US9592289B2 (en) * 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
WO2013148350A2 (en) * 2012-03-26 2013-10-03 Sanofi Anti-light antibody therapy for inflammatory bowel disease
CA2994719A1 (en) * 2015-08-21 2017-03-02 The Children's Hospital Of Philadelphia Methods of treating autoimmune conditions in patients with genetic variations in dcr3 or in a dcr3 network gene
PL3883606T3 (pl) * 2018-09-24 2023-11-27 Janssen Biotech, Inc. Bezpieczny i skuteczny sposób leczenia wrzodziejącego zapalenia jelita grubego przeciwciałami anty-il12/il23

Similar Documents

Publication Publication Date Title
JP2023517236A5 (enExample)
JP2011506483A5 (enExample)
JP2021526534A5 (enExample)
JP2018183173A5 (enExample)
CA2494008A1 (en) Anti-myelin associated glycoprotein (mag) antibodies
JP2023524149A5 (enExample)
JP2025032102A5 (enExample)
JP2019513726A5 (enExample)
JP2024531151A5 (enExample)
JPWO2020059847A5 (enExample)
IL263272B2 (en) Antibodies to coagulation factor xi
JP2022512647A5 (enExample)
JP2017534645A5 (enExample)
JP2021520393A5 (enExample)
JP2022532356A5 (enExample)
JP2024520202A5 (enExample)
CN101878037A (zh) 能够中和乙型肝炎病毒的人抗体在预防或治疗乙型肝炎病毒感染中的用途
JP2018529661A5 (enExample)
JP2025514978A5 (enExample)
WO2013140787A1 (ja) 特発性炎症性筋疾患の予防又は治療剤
JP2022529929A5 (enExample)
JP2023537078A5 (enExample)
JP2023546503A5 (enExample)
JP2021532176A5 (enExample)
JP2025515076A5 (enExample)